Movatterモバイル変換


[0]ホーム

URL:


SG11201407318UA - Compositions and methods for the treatment of metabolic syndrome - Google Patents

Compositions and methods for the treatment of metabolic syndrome

Info

Publication number
SG11201407318UA
SG11201407318UASG11201407318UASG11201407318UASG11201407318UASG 11201407318U ASG11201407318U ASG 11201407318UASG 11201407318U ASG11201407318U ASG 11201407318UASG 11201407318U ASG11201407318U ASG 11201407318UASG 11201407318U ASG11201407318U ASG 11201407318UA
Authority
SG
Singapore
Prior art keywords
international
formula
compositions
methods
metabolic syndrome
Prior art date
Application number
SG11201407318UA
Inventor
Mahesh Kandula
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private LtdfiledCriticalCellix Bio Private Ltd
Publication of SG11201407318UApublicationCriticalpatent/SG11201407318UA/en

Links

Classifications

Landscapes

Abstract

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 14 November 2013 (14.11.2013) WIPOIPCT (10) International Publication Number WO 2013/168016 A1 (51) International Patent Classification: C07F 9/09 (2006.01) A61P 3/00 (2006.01) C07C 309/63 (2006.01) A61P3/10 (2006.01) A61K31/683 (2006.01) (21) International Application Number: PCT/IB2013/051596 (22) International Filing Date: (25) Filing Language: (26) Publication Language: 28 February 2013 (28.02.2013) English English (30) Priority Data: 1853/CHE/2012 10 May 2012 (10.05.2012) IN (72) Inventor; and (71) Applicant : KANDULA, Mahesh [IN/IN]; Door No. 11- 61, Samalkot Mandal, East Godavari Dist, G.Medapadu 533 434, Andhra Pradesh (IN). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) V© i-H o 00 i-H en i-H o CJ o & (54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME (57) Abstract: The invention discloses the compounds of formula (I) and formula (II) or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula (I) or formula (II), and the methods of treating or preventing or modulating metabolic syndrome may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injec - tion. The compositions may be used treat to fasting hyperglycemia, diabetes mellitus type 2, impaired fasting glucose, impaired glue - ose tolerance, insulin resistance, high blood pressure, central obesity, overweight with fat deposits mainly around the waist, de­ creased HDL cholesterol, elevated triglycerides, hyperuricemia, fatty liver progressing to NAFLD, polycystic ovarian syndrome, hy­ pophosphatemia, renal diseases, albuminuria, end stage renal disease and acanthosis nigricans.
SG11201407318UA2012-05-102013-02-28Compositions and methods for the treatment of metabolic syndromeSG11201407318UA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
IN1853CH20122012-05-10
PCT/IB2013/051596WO2013168016A1 (en)2012-05-102013-02-28Compositions and methods for the treatment of metabolic syndrome

Publications (1)

Publication NumberPublication Date
SG11201407318UAtrue SG11201407318UA (en)2014-12-30

Family

ID=54193692

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201407318UASG11201407318UA (en)2012-05-102013-02-28Compositions and methods for the treatment of metabolic syndrome

Country Status (4)

CountryLink
US (1)US9403857B2 (en)
SG (1)SG11201407318UA (en)
WO (1)WO2013168016A1 (en)
ZA (1)ZA201408053B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US10743813B2 (en)2014-09-112020-08-18Rattan NathDiabetes control using postprandial feedback
CN111138332B (en)*2020-01-162021-10-26山东兴安动物药业有限公司Seleno-glycyrrhetinic acid, preparation method and application thereof

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US2807644A (en)1954-08-201957-09-24Parke Davis & CoPantethine inhibitors
DE1205972B (en)1963-08-201965-12-02Merck Ag E Process for the production of a lipoic acid derivative
US4011342A (en)1971-06-021977-03-08SepericMethod and composition for the treatment of hypertension with ortho-disubstituted arylguanidines
JPS5677259A (en)1979-11-291981-06-25Nippon Chemiphar Co LtdN-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation
JPS57500432A (en)1980-03-201982-03-11
US4404366A (en)1980-05-061983-09-13Miles Laboratories, Inc.Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4412992A (en)1980-07-211983-11-01Biorex Laboratories Limited2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith
US4440763A (en)1981-03-181984-04-03Block Drug Company, Inc.Use of 4-aminosalicyclic acid as an anti-inflammatory agent
IT1190727B (en)1982-03-101988-02-24Ausonia Farma Srl COMPOUND WITH ANALGESIC, ANTI-INFLAMMATORY AND MUCOREGULATING ACTIVITY PROCEDURE FOR ITS PREPARATION AND RELATED PHARMACEUTICAL COMPOSITIONS
FR2528038B2 (en)1982-06-041985-08-09Lafon Labor BENZHYDRYLSULFINYLACETAMIDE DERIVATIVES AND THEIR THERAPEUTIC USE
US4564628A (en)1983-01-031986-01-14Nelson Research & Development Co.Substituted 2-aminotetralins
US5104887A (en)1983-02-041992-04-14University Of Iowa Research FoundationTopical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors
JPS6089474A (en)1983-10-201985-05-20Toyo Pharma- KkMorphinan derivative, production thereof and antitumor agent containing said compound
IL73293A (en)1983-11-041988-02-29Abbott LabMethyl 2-(alkanamidoalkylsulfonic)ethylthiophosphonate derivatives
IT1213132B (en)1984-02-021989-12-14Yason Srl ANTIBRONCOPNEUMOPATHIC AGENT.
US4550109A (en)1984-05-311985-10-29The Board Of Regents, The University Of Texas SystemLipoidal biopterin compounds
JPS61277618A (en)1985-06-041986-12-08Suntory LtdRemedy for autism
YU213587A (en)1986-11-281989-06-30Orion Yhtymae OyProcess for obtaining new pharmacologic active cateholic derivatives
US4873259A (en)1987-06-101989-10-10Abbott LaboratoriesIndole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
US5120738A (en)1989-10-061992-06-09Fujirebio Inc.Pantothenic acid derivatives
US5242937A (en)1990-03-191993-09-07Research Corporation Technologies, Inc.Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors
IT1248702B (en)1990-06-061995-01-26Yason Srl ANTITUSSIVE AGENT AND MUCOREGULATOR, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS
FR2699077B1 (en)1992-12-161995-01-13Rhone Poulenc Rorer Sa Application of anticonvulsants in the treatment of neurological lesions linked to trauma.
FR2707637B1 (en)1993-06-301995-10-06Lafon Labor New acetamide derivatives, their preparation process and their use in therapy.
CA2183562A1 (en)1994-02-181995-08-24J. Peter KleinIntracellular signalling mediators
SE9401727D0 (en)1994-05-181994-05-18Astra Ab New compounds I
FR2722199B3 (en)1994-07-111996-09-06Univ Picardie Jules Verne Etab VALPROIC ACID DERIVATIVES AND THEIR APPLICATIONS AS MEDICAMENTS
US6156777A (en)1994-12-152000-12-05Pharmacia & Upjohn CompanyUse of pramipexole as a neuroprotective agent
NZ334389A (en)1996-08-282001-05-25Ube IndustriesCyclic amine derivatives
ATE296797T1 (en)1996-11-222005-06-15Elan Pharm Inc N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS THEREFOR, AND METHODS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE OR SYNTHESIS
US6414008B1 (en)1997-04-292002-07-02Boehringer Ingelheim Pharma KgDisubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
GB9710351D0 (en)1997-05-201997-07-16Scotia Holdings PlcGlucosamine fatty acids
NZ333474A (en)1998-01-021999-06-29Mcneil Ppc IncA chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
RU2203887C2 (en)1998-02-272003-05-10Санкио Компани, ЛимитедCyclic amino-derivatives, pharmaceutical composition and method of disease prophylaxis
JP3761324B2 (en)1998-05-152006-03-29ヤンマー農機株式会社 Passenger rice transplanter
US6846495B2 (en)1999-01-112005-01-25The Procter & Gamble CompanyCompositions having improved delivery of actives
ES2305606T3 (en)1999-04-062008-11-01Sepracor Inc. O-DEMETILVENLAFAXIN SUCCINATE.
US6262118B1 (en)1999-06-042001-07-17Metabolex, Inc.Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
CN1211085C (en)1999-09-292005-07-20宝洁公司Compositions having improved stability
US6429223B1 (en)2000-06-232002-08-06Medinox, Inc.Modified forms of pharmacologically active agents and uses therefor
AU2001279064A1 (en)2000-07-272002-02-13Rutgers, The State UniversityTherapeutic azo-compounds for drug delivery
KR100810930B1 (en)2000-10-242008-03-10아지노모토 가부시키가이샤 Method for preparing nateglinide crystal form
DE10103506A1 (en)2001-01-262002-08-14Ingo S Neu Pharmaceutical composition for the treatment of multiple sclerosis
UA81224C2 (en)2001-05-022007-12-25Euro Celtic S ADosage form of oxycodone and use thereof
AU2002326806B2 (en)2001-08-292007-07-19Endo Pharmaceuticals, Inc.Analgetic pyrroline derivatives
US7138133B2 (en)2001-10-102006-11-21The Procter & Gamble CompanyOrally administered liquid compositions
US20040010038A1 (en)2002-02-272004-01-15Eran BlaugrundPropargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US20030220344A1 (en)2002-04-042003-11-27Luiz BelardinelliMethod of treating arrhythmias
AU2003242520A1 (en)2002-04-152003-10-27Novartis AgCrystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine
KR20040101381A (en)2002-04-162004-12-02후지사와 야꾸힝 고교 가부시키가이샤New use
US7060725B2 (en)2002-05-132006-06-13Janssen Pharmaceutica N.V.Substituted sulfamate anticonvulsant derivatives
GB0223224D0 (en)2002-10-072002-11-13Novartis AgOrganic compounds
AU2003293423A1 (en)2002-12-062004-06-30Xenoport, Inc.Carbidopa prodrugs and uses thereof
AU2003303196C1 (en)2002-12-192021-03-25The Scripps Research InstituteCompositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
MXPA05008652A (en)2003-02-142005-10-18Pf MedicamentUse of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament.
UA81657C2 (en)2003-03-042008-01-25Орто-Макнейл Фармасьютикел, Инк.Normal;heading 1;heading 2;PROCESS FOR THE PREPARATION OF ANTICONVULSANT DERIVATIVES OF TOPIRAMATE
NZ601772A (en)2003-07-292012-10-26Signature R & D Holdings LlcAmino Acid Prodrugs
RU2412162C2 (en)2003-10-142011-02-20Ксенопорт, Инк.Crystalline form of (-aminobutyric acid analogue
US7470435B2 (en)2003-11-172008-12-30Andrx Pharmaceuticals, LlcExtended release venlafaxine formulation
NZ547401A (en)2003-11-282008-06-30Sankyo CoCyclic amine derivative having heteroaryl ring
DE10361259A1 (en)2003-12-242005-07-28Schwarz Pharma Ag Use of Rotigotine in Early Stage Parkinson's Disease to Prevent Further Neuronal Loss
CN1248690C (en)2004-03-252006-04-05华中师范大学Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease
AU2005248294A1 (en)2004-04-072005-12-08The University Of Georgia Research Foundation, Inc.Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods
US20050244486A1 (en)2004-04-292005-11-03Caldwell Larry JTopical methadone compositions and methods for using the same
CN1672678A (en)2004-05-032005-09-28深圳微芯生物科技有限责任公司Separation and extraction of natural active long-chain fatty acid component for preventing and treating prostatosis and the prepn and application of its medicine prepn
WO2005121069A1 (en)2004-06-042005-12-22Xenoport, Inc.Levodopa prodrugs, and compositions and uses thereof
CN100455560C (en)2004-06-092009-01-28中国人民解放军军事医学科学院放射医学研究所Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use
EP1863433A4 (en)2005-03-182009-09-09Ripped Formulations LtdCompositions and methods for increasing metabolism, thermogenesis and/or muscular definition
BRPI0612796A2 (en)2005-05-112010-11-30Nycomed Gmbh combination of a pde4 inhibitor and a tetrahydrobiopterin derivative
DE102005022276A1 (en)2005-05-132006-11-16Ellneuroxx Ltd. Derivatives of dihydroxyphenylalanine
US20060270635A1 (en)2005-05-272006-11-30Wallace John LDerivatives of 4- or 5-aminosalicylic acid
WO2006125293A1 (en)*2005-05-272006-11-30Antibe Therapeutics Inc.Derivatives of 4- or 5-aminosalicylic acid
AU2006250335B2 (en)2005-05-272010-09-02Daiichi Sankyo Company, LimitedCyclic amine derivative having substituted alkyl group
WO2007045620A1 (en)2005-10-182007-04-26Boehringer Ingelheim International GmbhUse of pramipexol for treating moderate to severe restless legs syndrome (rls)
CN101374552A (en)2006-01-272009-02-25旭化成制药株式会社Medicine for transnasal administration
WO2007121188A2 (en)2006-04-102007-10-25Knopp Neurosciences, Inc.Compositions and methods of using r(+) pramipexole
EP1870395A1 (en)2006-06-192007-12-26KRKA, D.D., Novo MestoProcess for preparation of o-desmethylvenlafaxine and its analogue
US7943666B2 (en)2006-07-242011-05-17Trinity Laboratories, Inc.Esters of capsaicin for treating pain
US7645767B2 (en)2006-08-312010-01-12Trinity Laboratories, Inc.Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
TW200817048A (en)2006-09-082008-04-16Wyeth CorpDry powder compound formulations and uses thereof
EP2101766B1 (en)2006-12-142016-09-21Knopp Biosciences LLCCompositions and methods of using (r)-pramipexole
CN100573950C (en)2006-12-142009-12-23财团法人工业技术研究院Phase change memory device and method of manufacturing the same
EP2063867A2 (en)2006-12-222009-06-03Combinatorx, IncorporatedPharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008206486C1 (en)2007-01-122013-09-26Biomarin Pharmaceutical Inc.Tetrahydrobiopterin prodrugs
ES2319024B1 (en)2007-02-132009-12-11Quimica Sintetica, S.A. PROCEDURE FOR OBTAINING ENTACAPONA SUBSTANTIALLY FREE OF ISOMERO Z, ITS SYNTHESIS INTERMEDIATES AND NEW CRYSTAL FORM.
CA2681110A1 (en)2007-03-142008-09-18Knopp Neurosciences, Inc.Synthesis of chirally purified substituted benzothiazole diamines
DK2345653T3 (en)2007-05-012013-04-08Concert Pharmaceuticals Inc Morphinan compounds
EP1997493A1 (en)2007-05-282008-12-03Laboratorios del Dr. Esteve S.A.Combination of a 5-HT7 receptor ligand and an opioid receptor ligand
CA2690776A1 (en)2007-06-222008-12-31Gluconova LlcHalide-free glucosamine-acidic drug complexes
US20090075942A1 (en)*2007-09-132009-03-19Protia, LlcDeuterium-enriched fosamprenavir
CN101390854A (en)2007-09-212009-03-25北京德众万全药物技术开发有限公司Medical composition containing riluzole
WO2009056791A1 (en)2007-11-022009-05-07Pliva Hrvatska D.O.O.Processes for preparing pharmaceutical compounds
US20090118365A1 (en)2007-11-062009-05-07Xenoport, IncUse of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
CN101186583B (en)2007-12-202011-05-11吉林大学Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application
US20100081713A1 (en)2008-03-192010-04-01CombinatoRx, (Singapore) Pte. Ltd.Compositions and methods for treating viral infections
CN102512405B (en)2008-04-302015-08-05上海医药工业研究院One class long-chain fatty acid derivative or the plant extract containing it are preparing the application in the medicine suppressing activity of aromatizing enzyme
WO2009148698A1 (en)*2008-06-022009-12-10Cedars-Sinai Medical CenterNanometer-sized prodrugs of nsaids
KR100990949B1 (en)2008-06-092010-10-29엔자이텍 주식회사 Method for preparing clopidogrel and its derivatives
SI2315740T1 (en)2008-07-082018-03-30Catabasis Pharmaceuticals, Inc.Fatty acid acetylated salicylates and their uses
AU2009282888C1 (en)2008-08-192014-01-23Xenoport, Inc.Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
UA106877C2 (en)2008-08-222014-10-27Вокхардт Рісерч СентерAn extended release pharmaceutical composition of entacapone or salts thereof
US20110313176A1 (en)2008-12-262011-12-22Actavis Group Ptc EhfProcesses for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof
BRPI0901298A2 (en)2009-04-062011-01-04Ems Sa phthalimide derivatives of nonsteroidal antiinflammatory compounds and / or modulators of tnf- (alpha), process for obtaining them, pharmaceutical compositions containing them and their uses in the treatment of inflammatory diseases
EP4008327A1 (en)2009-04-292022-06-08Amarin Pharmaceuticals Ireland LimitedPharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010147666A1 (en)2009-06-192010-12-23Memorial Sloan-Kettering Cancer CenterCompounds useful as carbonic anhydrase modulators and uses thereof
SG10201600910YA (en)2009-08-102016-03-30Bhi Ltd PartnershipMethods, compounds, and compositions for delivering 1,3-propanedisulfonic acid
CN102002053A (en)2009-09-022011-04-06陕西合成药业有限公司Tetrahydro thienopyridine derivative for treating
CN101717392A (en)2009-10-092010-06-02苏州凯达生物医药技术有限公司Method for preparing rotigotine and derivative thereof
CN102050815B (en)2009-11-062014-04-02北京美倍他药物研究有限公司Dabigatran ester derivatives as prodrug
CN101724934B (en)2009-11-102012-07-04东华大学Medicinal fibre used for treating cutaneous inflammation and pain, preparation and application thereof
ES2364011B1 (en)2009-11-202013-01-24Gp Pharm, S.A. CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES.
MY160249A (en)2010-01-082017-02-28Catabasis Pharmaceuticals IncFatty acid fumarate derivatives and their uses
WO2011089216A1 (en)2010-01-222011-07-28Ascendis Pharma AsDipeptide-based prodrug linkers for aliphatic amine-containing drugs
RU2436772C2 (en)2010-01-282011-12-20Закрытое акционерное общество "НПК ЭХО"4[(4'-nicotinoylamino)butyroylamino]butanoic acid, exhibiting nootropic activity, and method of producing said compound
US20130190327A1 (en)2010-02-262013-07-25Catabasis Pharmaceuticals IncBis-fatty acid conjugates and their uses
BR112012031194A2 (en)2010-06-082018-05-29Krisani Biosciences P Ltd cysteamine derivatives and their use in the treatment of ehna
BR112013000537B1 (en)2010-07-122021-07-27Boehringer Ingelheim International Gmbh AQUEOUS COMPOSITION CONTAINING BROMEXINE AND ITS USE
AR082499A1 (en)2010-08-232012-12-12Gruenenthal Gmbh USEFUL COMPOUNDS FOR NERVOUS SYSTEM, INFLAMMATORY, STOMACH AND AS ANALGESIC DISORDERS
WO2012027543A1 (en)2010-08-252012-03-01Teva Pharmaceuticals Usa, Inc.Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof
CN101921245B (en)2010-08-302012-04-18中国人民解放军军事医学科学院卫生学环境医学研究所Sulfonamide compound for inhibiting carbonic anhydrase II, and synthesis method and application thereof
CA2814371C (en)2010-10-292019-03-19Algiax Pharmaceuticals GmbhUse of malononitrilamides in neuropathic pain
EP2450039A1 (en)2010-11-082012-05-09PAION UK Ltd.Dosing regimen for sedation with CNS 7056 (Remimazolam)
WO2012115695A1 (en)2011-02-252012-08-30Catabasis Pharmaceuticals, Inc.Bis-fatty acid conjugates and their uses
WO2013008182A1 (en)2011-07-102013-01-17Mahesh KandulaProdrugs of gaba analogs
CN102336767A (en)2011-07-112012-02-01华东理工大学Method for preparing high-purity chiral alpha-substituted-6,7-thiaindan[3,2-c]pyridine derivative
WO2013017974A1 (en)2011-07-302013-02-07Mahesh KandulaCompositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases
WO2013024376A1 (en)2011-08-162013-02-21Mahesh KandulaCompositions and methods for the treatment of atherothrombosis
WO2013027150A1 (en)2011-08-212013-02-28Mahesh KandulaCompositions and methods for the treatment of parkinson's disease
CN102633799B (en)2012-04-102014-06-25凯莱英医药集团(天津)股份有限公司Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route
US20150133533A1 (en)2012-05-082015-05-14Mahesh KandulaCompositions and methods for the treatment of cough
WO2013168022A1 (en)2012-05-082013-11-14Mahesh KandulaCompositions and methods for treating atherothrombosis
WO2013167993A1 (en)2012-05-082013-11-14Mahesh KandulaCompositions and methods for the treatment of neurological degenerative disorders
WO2013167996A1 (en)2012-05-102013-11-14Mahesh KandulaCompositions and methods for the treatment of metabolic syndrome

Also Published As

Publication numberPublication date
US20150080345A1 (en)2015-03-19
US9403857B2 (en)2016-08-02
WO2013168016A1 (en)2013-11-14
ZA201408053B (en)2016-04-28

Similar Documents

PublicationPublication DateTitle
SG11201407411SA (en)Compositions and methods for the treatment of metabolic syndrome
SG11201408094YA (en)Neprilysin inhibitors
SG11201407326XA (en)Compositions and methods for treatment of mucositis
SG11201804577RA (en)Fgf21 variants
SG11201408769QA (en)Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
SG11201407533SA (en)Antiviral compounds
SG11201809344QA (en)Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201407037UA (en)Catechol o-methyltransferase activity inhibiting compounds
SG11201408539UA (en)Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
SG11201408095XA (en)Fibroblast growth factor 21 proteins
SG11201408739VA (en)Inhibitors of hepatitis c virus
SG11201408324QA (en)Pyridinone and pyridazinone derivatives
SG11201407115XA (en)Carboxylic acid compounds
SG11201908325PA (en)Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201403402VA (en)Compounds
SG11201909376TA (en)Crystalline forms of a jak inhibitor compound
IL213323A (en)Agent for prevention and/or treatment of an allergic disease comprising a low-molecular-weight polysulfated hyaluronic acid derivative, use of same or a pharmaceutically acceptable salt thereof, as well as a low-molecular-weight polysulfated hyaluronic acid derivative and pharmaceutical composition containing same
SG11201407591PA (en)Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
SG11201407323WA (en)Compositions and methods for the treatment of local pain
SG11201407184PA (en)Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201407319YA (en)Compositions and methods for treatment of inflammatory bowel disease
SG11201408750VA (en)NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201407303SA (en)Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
SG11201809221WA (en)Administration of berberine metabolites
SG11201407317SA (en)Compositions and methods for suppression of carbonic anhydrase activity

[8]ページ先頭

©2009-2025 Movatter.jp